Cargando…
Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes
The identification of minimal residual disease is the primary diagnostic finding which predicts relapse in patients treated for acute myeloid leukemia. Ultrasensitive detection of minimal residual disease would enable better patient risk stratification and could open opportunities for early therapeu...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685235/ https://www.ncbi.nlm.nih.gov/pubmed/28572161 http://dx.doi.org/10.3324/haematol.2017.169136 |
_version_ | 1783278603603017728 |
---|---|
author | Waalkes, Adam Penewit, Kelsi Wood, Brent L. Wu, David Salipante, Stephen J. |
author_facet | Waalkes, Adam Penewit, Kelsi Wood, Brent L. Wu, David Salipante, Stephen J. |
author_sort | Waalkes, Adam |
collection | PubMed |
description | The identification of minimal residual disease is the primary diagnostic finding which predicts relapse in patients treated for acute myeloid leukemia. Ultrasensitive detection of minimal residual disease would enable better patient risk stratification and could open opportunities for early therapeutic intervention. Herein we apply single molecule molecular inversion probe capture, a technology combining multiplexed targeted sequencing with error correction schemes based on molecular barcoding, in order to detect mutations identifying minimal residual disease with ultrasensitive and quantitative precision. We designed a single molecule molecular inversion probe capture panel spanning >50 kb and targeting 32 factors relevant to acute myeloid leukemia pathogenesis. We demonstrate linearity and quantitative precision over 100-fold relative abundance of mutant cells (1 in 100 to 1 in 1,500), with estimated error rates approaching 1 in 1,200 base pairs sequenced and maximum theoretical limits of detection exceeding 1 in 60,000 mutant alleles. In 3 of 4 longitudinally collected specimens from patients with acute myeloid leukemia, we find that single molecule molecular inversion probe capture detects somatic mutations identifying minimal residual disease at substantially earlier time points and with greater sensitivity than clinical diagnostic approaches used as current standard of care (flow cytometry and conventional molecular diagnosis), and identifies persisting neoplastic cells during clinical remission. In 2 patients, single molecule molecular inversion probe capture detected heterogeneous, subclonal acute myeloid leukemia populations carrying distinct mutational signatures. Single molecule molecular inversion probe technology uniquely couples scalable target enrichment with sequence read error correction, providing an integrated, ultrasensitive approach for detecting minimal residual disease identifying mutations. |
format | Online Article Text |
id | pubmed-5685235 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Ferrata Storti Foundation |
record_format | MEDLINE/PubMed |
spelling | pubmed-56852352017-11-21 Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes Waalkes, Adam Penewit, Kelsi Wood, Brent L. Wu, David Salipante, Stephen J. Haematologica Article The identification of minimal residual disease is the primary diagnostic finding which predicts relapse in patients treated for acute myeloid leukemia. Ultrasensitive detection of minimal residual disease would enable better patient risk stratification and could open opportunities for early therapeutic intervention. Herein we apply single molecule molecular inversion probe capture, a technology combining multiplexed targeted sequencing with error correction schemes based on molecular barcoding, in order to detect mutations identifying minimal residual disease with ultrasensitive and quantitative precision. We designed a single molecule molecular inversion probe capture panel spanning >50 kb and targeting 32 factors relevant to acute myeloid leukemia pathogenesis. We demonstrate linearity and quantitative precision over 100-fold relative abundance of mutant cells (1 in 100 to 1 in 1,500), with estimated error rates approaching 1 in 1,200 base pairs sequenced and maximum theoretical limits of detection exceeding 1 in 60,000 mutant alleles. In 3 of 4 longitudinally collected specimens from patients with acute myeloid leukemia, we find that single molecule molecular inversion probe capture detects somatic mutations identifying minimal residual disease at substantially earlier time points and with greater sensitivity than clinical diagnostic approaches used as current standard of care (flow cytometry and conventional molecular diagnosis), and identifies persisting neoplastic cells during clinical remission. In 2 patients, single molecule molecular inversion probe capture detected heterogeneous, subclonal acute myeloid leukemia populations carrying distinct mutational signatures. Single molecule molecular inversion probe technology uniquely couples scalable target enrichment with sequence read error correction, providing an integrated, ultrasensitive approach for detecting minimal residual disease identifying mutations. Ferrata Storti Foundation 2017-09 /pmc/articles/PMC5685235/ /pubmed/28572161 http://dx.doi.org/10.3324/haematol.2017.169136 Text en Copyright© 2017 Ferrata Storti Foundation Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher. |
spellingShingle | Article Waalkes, Adam Penewit, Kelsi Wood, Brent L. Wu, David Salipante, Stephen J. Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes |
title | Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes |
title_full | Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes |
title_fullStr | Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes |
title_full_unstemmed | Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes |
title_short | Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes |
title_sort | ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685235/ https://www.ncbi.nlm.nih.gov/pubmed/28572161 http://dx.doi.org/10.3324/haematol.2017.169136 |
work_keys_str_mv | AT waalkesadam ultrasensitivedetectionofacutemyeloidleukemiaminimalresidualdiseaseusingsinglemoleculemolecularinversionprobes AT penewitkelsi ultrasensitivedetectionofacutemyeloidleukemiaminimalresidualdiseaseusingsinglemoleculemolecularinversionprobes AT woodbrentl ultrasensitivedetectionofacutemyeloidleukemiaminimalresidualdiseaseusingsinglemoleculemolecularinversionprobes AT wudavid ultrasensitivedetectionofacutemyeloidleukemiaminimalresidualdiseaseusingsinglemoleculemolecularinversionprobes AT salipantestephenj ultrasensitivedetectionofacutemyeloidleukemiaminimalresidualdiseaseusingsinglemoleculemolecularinversionprobes |